Physician profile
Henry Beecher
NPI 1396949582
$18,552.75
in general payments reported to CMS, 2019-2025
43 companies · $3,346 in 2025
The $3,346 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,221 · 2020: $1,791 · 2021: $2,415 · 2022: $2,974 · 2023: $2,641 · 2024: $3,164 · 2025: $3,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,151.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,600.12 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,544.69 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,939.89 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $1,498.51 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,434.87 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $872.77 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $551.73 | 2023-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $519.83 | 2019-2024 | Linzess |
| Madrigal Pharmaceuticals | $438.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $391.24 | 2021-2024 | Zeposia |
| Redhill Biopharma INC. | $386.74 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Ipsen Biopharmaceuticals, INC | $350.40 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $307.52 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $289.68 | 2020-2023 | |
| Qol Medical, LLC | $261.41 | 2022-2025 | Sucraid, Sucraid |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $247.92 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $221.22 | 2019-2024 | Dificid |
| Ardelyx, INC. | $196.71 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $181.76 | 2019-2024 | Rebyota, Cimzia |
| Exact Sciences Corporation | $162.52 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $161.95 | 2024-2025 | Omvoh |
| Allergan, INC. | $160.53 | 2019-2020 | |
| Boston Scientific Corporation | $156.57 | 2021-2024 | |
| Concordia Pharmaceuticals INC. | $98.70 | 2019 | |
| Amgen INC. | $70.46 | 2023-2025 | Amjevita, Avsola, Uplizna |
| Vivus LLC | $67.72 | 2025 | Pancreaze, Qsymia |
| Intercept Pharmaceuticals, INC. | $53.16 | 2020-2025 | |
| Lucid Diagnostics INC. | $45.39 | 2023 | |
| Biocon Biologics INC | $44.38 | 2024-2025 | Hulio, Yesintek |
| Novo Nordisk INC | $39.75 | 2025 | Wegovy |
| Endogastric Solutions, INC | $35.64 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $30.85 | 2023 | Fujifilm |
| Echosens North America, INC. | $24.32 | 2023 | Fibroscan |
| Alnylam Pharmaceuticals INC. | $24.18 | 2022 | |
| Ucb, INC. | $20.67 | 2019 | |
| Intra-Sana Laboratories | $20.65 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Sandoz INC. | $20.23 | 2023 | |
| Portola Pharmaceuticals, LLC | $17.71 | 2019 | |
| Endo Pharmaceuticals INC. | $16.96 | 2019 | |
| Shionogi INC | $15.79 | 2020 | |
| Shire North American Group INC | $15.07 | 2019 | |
| Evoke Pharma, INC. | $13.64 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,907.04 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Beecher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.